Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT00776425
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Phase 1
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT00776698
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00774241
A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Drug: epoetin beta
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 281
- Registration Number
- NCT00773331
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
Phase 2
Terminated
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: RG1507Drug: erlotinib [Tarceva]
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT00773383
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
Phase 1
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT00773188
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: RO5126766
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00773526
A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00773968
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT00773695
- Locations
- 🇳🇴
Ullevael Sykehus; Dept of Oncology, Oslo, Norway
🇳🇴The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway
🇳🇴St. Olavs Hospital; Kreftavdelingen, Trondheim, Norway
A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: tocilizumab [RoActemra/Actemra]Drug: Placebo
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 209
- Registration Number
- NCT00773461
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳General Hospital of Chinese PLA; Department of Hematology, Beijing, China
🇨🇳Beijing Union Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath